Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New eczema drug tested in major Real-World trial

NCT ID NCT07276620

Summary

This study is testing how well an already-approved eczema medication called ivarmacitinib works in everyday practice. It will enroll 1,000 teens and adults with moderate-to-severe atopic dermatitis to measure how quickly itching improves and skin clears up. The research also aims to collect safety data and see how different maintenance treatment plans affect whether the eczema comes back.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS (AD) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.